Table 1.
Immunological examination of the patient.
| Parameter | 19 Days of Life * | 12 Months of Life | Normal Range |
|---|---|---|---|
| T cells (CD3+), 109/L | 1.92 | 2.01 | 3.3–6.5 (58–71%) |
| Th (CD4+), 109/L (% of T cells) | 1.22 (63.4%) | 1.15 (57.2%) | 1.9–4.4 (56–79%) |
| Th naïve (CD45RA+CD197+), cells/µL (% of CD4+) | 809 (66.2%) | 773.52 (67.2%) | 1442–3731 (72–86%) |
| T-central memory, cells/µL (% of CD4+) | 284 (23.3%) | 115(10%) | 151–448 (4.5–15.1%) |
| Effector memory, cells/µL (% of CD4+) | 105 (8.6%) | 199 (17.3%) | 126–399 (4.2–13.9) |
| TEMRA, cells/µL (% of CD4+) | 24 (2%) | 64 (5.6%) | 36–225 (1.3–6.9%) |
| Tc (CD8+), 109/L (% of T cells) | 0.66 (34%) | 0.73 (36.1%) | 0.7–1.9 (18–39%) |
| Tc naïve (CD45RA+CD197+), cells/µL (% of CD8+ cells) | 600 (91.5%) | 352 (48.5%) | 455–1515 (34–88%) |
| T-central memory, cells/µL (% of CD8+) | 37 (5.6%) | 18 (2.6%) | 6–85 (0.4–8.0%) |
| Effector memory, cells/µL (% of CD8+) | 11 (1.7%) | 245 (33%) | 50–395 (3.4–24.4%) |
| TEMRA, cells/µL (% of CD8+) | 9 (1.3%) | 109 (15.1%) | 69–736 (6.1–39.0%) |
| B cells (CD19+), 109/L (% of Lymphocytes) | 1.78 (40%) | 2.57 (45%) | 1–3 (17–36%) |
| B naïve (CD19+IgD+IgM+CD27−), cells/µL (% of B cells) | n/a | 2360 (91.9%) | 290–1637 (62–83%) |
| Transitional B cells (CD19+IgM+CD38+), cells/µL (% of B cells) | n/a | 41 (1.6%) | 32–235 (3.4–11.9%) |
| Natural effector B cells (IgD+IgM+CD27+), cells/µL (% of B cells) | n/a | 67 (2.6%) | 15–242 (2.7–14.6%) |
| IgM-only B cells (CD27+IgM+IgD−), cells/µL (% of B cells) | n/a | 5 (0.2%) | 2–28 (0.2–2.0%) |
| Switched B memory cells (IgD−IgM−CD27+), cells/µL (% of B cells) | n/a | 36 (1.4%) | 5–83 (0.5–5.1%) |
| Plasmablasts (CD19+IgD−IgM−CD27+CD38high), cells/µL (% of B cells) | n/a | 2.6 (0.1%) | 1–28.5 (0.07–3.17%) |
| Plasma B cells (CD19+IgD−IgM−CD27+CD38highCD138+), cells/µL (% of B cells) | n/a | 0 (0%) | – |
| CD21lowCD38low B cells, cells/µL (% of B cells) | n/a | 72 (2.8%) | 7–75 (1.1–5.0%) |
| NK cells (CD3−CD16+CD56+), 109/L (% of Lymphocytes) | 0.7 (15.9%) | 0.9 (16.1%) | 0.2–1.3 (3–16%) |
| CD56+high NK, cell/µL (% of NK-cells) | 100 (15.6%) | 70 (14%) | 10–160 (2.6–15.3%) |
| T-NK-cells CD3+CD56+, cell/µL (% of Lymphocytes) | 0 | 6 (0.1%) | 5–30 (0.05–0.39%) |
| IgG, g/L | n/a | 7.02 | 4.75–12.10 |
| IgM, g/L | n/a | 0.87 | 0.41–1.83 |
| IgA, g/L | n/a | 0.55 | 0.21–2.91 |
* n/a—not assessed.